Skip to main content

Dr. Curtis J. Mello, MD

Pulmonology (Pulmonary Disease Physician)

  • Medicare participating

At a glance

Years since graduation
37
In the NPI registry since
2006
Medicare patients seen, 2024
757

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1989Medical school: Boston University School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Pulmonary Disease Physician primary
    MA license 79856 · RI license MD07880

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Pulmonology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
757
Services billed
2,472
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 20-29 minutes1,088691
Established patient office or other outpatient visit, 30-39 minutes403239
Test to measure expiratory airflow and volume changes before and after medication administration201198
Test to examine how well the lungs exchange gases189189
New patient office or other outpatient visit, 45-59 minutes167167
Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes16759
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg154154
Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes14553
Test to determine lung volumes using gas dilution or washout142137
New patient office or other outpatient visit, 30-44 minutes134134

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 29 payments worth $5,952 in total to this clinician.

By company
Viatris Specialty LLC$3,037
Chiesi USA, Inc.$2,377
AstraZeneca Pharmaceuticals LP$221
GlaxoSmithKline, LLC.$183
Amgen Inc.$53.73
Verona Pharma, Inc.$34.09
Boehringer Ingelheim Pharmaceuticals, Inc.$25.47
3b Medical, Inc.$20.64
By type
Compensation for services other than consulting (speaking, faculty)$3,018
Travel and Lodging$2,288
Food and Beverage$612
Education$34.00

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jan 24, 2025Chiesi USA, Inc.
Jan 24, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
$2,288
Sep 9, 2025Viatris Specialty LLC
Sep 9, 2025
Compensation for services other than consulting (speaking, faculty)
YUPELRI · Anticholinergics, Inhaled
$2,012
Sep 25, 2025Viatris Specialty LLC
Sep 25, 2025
Compensation for services other than consulting (speaking, faculty)
YUPELRI · Anticholinergics, Inhaled
$1,006
Aug 29, 2025Amgen Inc.
Aug 29, 2025
Education
in-kind
$34.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Massachusetts →

Industry-funded research

Named as a principal investigator on 14 industry-funded studies in 2025, from 7 companies. The companies reported $128,578 in research payments for these studies, mostly to the institutions running them.

  • A phase 3, 52-week, randomized, double-blind, placebo-controlled, para
    GlaxoSmithKline, LLC.
  • A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
    Teva Pharmaceuticals USA, Inc.
  • Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary D…
    AstraZeneca Pharmaceuticals LP
  • A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
    United Therapeutics Corporation · Recruiting · NCT05943535
  • A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chron…
    AstraZeneca Pharmaceuticals LP
  • An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obs…
    AstraZeneca Pharmaceuticals LP
  • A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
    Eli Lilly and Company · Completed · NCT04255433
  • A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
    Boehringer Ingelheim Pharmaceuticals, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pulmonology clinicians in North Dartmouth

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 24, 2020), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1124080312. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.